OBJECTIVE: To examine whether having metabolic syndrome (MS) among seniors is associated with using antidepression medication.
Introduction:
Available epidemiological evidence suggests that depression among the elderly is a significant public health problem both for its effect on quality of life and for its impact on expected lifespan [1, 2] . With an estimated prevalence of 4% among the US household population aged 60+, approximately 2.5 million in this age group suffer from depression based on 2010 -2014
American Community Survey estimated figures [3] .
Moreover, depression in seniors is considered as one of the most common conditions associated with suicide.
Although people aged 60+ comprise only 19.5 percent of US population in 2014, they accounted 25.5 percent of total suicide deaths [4] . In that year, 18.6 of every 100,000 people aged 60 and older died by suicide; it is significantly higher than the rate of 13.4 per 100,000 in the general population.
There is no doubt that medication treatment for seniors with serious depression is important and necessary. However, seniors are often with large degree of medical co-morbidity, especially vascular diseases, or with much unfavorable profile of inflammatory and metabolic dysregulations, which may contribute to the development of depression in late life [5] [6] [7] [8] [9] [10] ; while antidepressants use are often associated with weight gain and metabolic abnormalities [11] [12] [13] . As drug therapy is often selected as a primary mode of management in depression and the antidepressants now rank as the most frequently dispensed prescription medication in the US [14] , the risk for metabolic syndrome (MS) among seniors is particularly a concern.
MS is a clustering of risk factors known to promote or increase the risk of cardiovascular disease including impaired glucose metabolism, hypertension, dyslipidemia and abdominal obesity [15] [16] [17] . Thus, it is necessary to be caution in regarding using antidepressants among the elderly to minimize cardiovascular risk. However, it seems no study only focus on seniors to examine how MS and its risk profile are affected by taking antidepressant drugs and whether using anti-depressant drugs is the only explanation for the observed cardiometabolic risk association with using anti-depressant drugs. In this study, using the National Health and Nutrition Examination Survey (NHANES) 2008 dataset, we explored whether such an association can be identified.
Methods

Study Population:
Our study was based on public domain data The original NHANES database included self-reports on 2145 persons aged 60 and older. Within this age bracket we excluded from analysis those who provided incomplete information on prescription drug use in the preceding month and those who reported a history of either CVD (i.e., yes with either coronary heart disease, congestive heart failure, heart attack, stroke, or angina) or cancer (i.e., any type cancer or malignancy), leaving a sample size of 1366 subjects (617 men and 749 women).
Prescription 'Drug Use' Variable:
When survey participants responded 'yes' to the question on prescription medication use during the past month, further information would be gathered regarding each generic drug name and its duration of use. In 86% of cases a check of medication containers made verification of details possible. In this study, we defined three drug use categories: (1) 
Covariates:
Covariates included in the analysis were age To examine whether depression as detected by the PHQ -9 screening tool may be associated with a risk of MS, we specified a binary indicator to classify summary scores as either screen-positive for mild to severe depression (PHQ-9≥5) or screen-negative (PHQ-9 <5).
Analysis was conducted only among persons in group 1 females respectively having used anti-depressants.
Among those who reported taking anti-depressant drugs, approximately 82% of them were on selective serotonin reuptake inhibitors (SSRIs). Characteristics of the sample selected for analysis are shown in Table 1 .
Gender differences were few in statistically significance. the results were similar. Those who took antidepressants were from two subgroups, i.e., a) the duration of taking non-anti-depressant medications is longer than that of taking anti-depressant medications, and b) taking antidepressants alone or its duration is longer than that of taking non-anti-depressant medications. However, when further dividing those who took anti-depressants into two subgroups in the models, the results were similar to To generate the results in Table 4 , we used a surrogate measure of drug exposure as described in the Methods section above. No increased odds of MS was evident as a result of relatively prolonged exposure to anti-depressants where non-antidepressant drug users became the referent.
The prevalence of depression detected by the PHQ-9 screening tool (PHQ-9≥5) was 8.6% for males and 11.4% for females among group 1 (non-users) and (moderate or more severe depression).
Discussion:
Using the NHANES 2007-08 data we examined the cardio-metabolic risk association with antidepressants drug use among US seniors and found that in comparing to no drug users, seniors with prescribed anti-depressants were in more than two times higher odds of having MS. The high odds of MS association with using anti-depressant drugs have been observed by several different studies [12, 13, 20] . For instance, results from the PPP-Botnia Study conducted among Finns aged 18-75 years indicated that users of antidepressant drugs had more than 50% higher odds of MS in comparing to non-users [12] , and the cohort study conducted in Italy showed that in the general population without treated cardiovascular risk, pharmacologic treatment for depression was associated with about twofold higher risk in all-cause mortality and major cardiovascular outcomes [20] . However, the observed cardio-metabolic risk association in our study seems not to be explained well as the result of taking antidepressants because in comparing to those who were not on any prescribed drugs, the seniors with antidepressants had a similar level of odds of MS as those with non-antidepressant drugs. In addition, the cardio-metabolic risk profiles were very similar between these two groups; in general, both of them had much higher odds of diabetes and hypertension in comparing to non-drug users.
Although results from some other studies suggested that the increased cardio-metabolic risk may be associated with the severity of mental health status [13, 21] , our results from those who were not on antidepressants, however, failed to support the association. It seems the odds of having MS for those with depression measured by PHQ-9 score equal or higher than five was similar to those with a score less than five. The different results could be due to the differences between our study and others on age of the study subjects (ours were aged 60+ vs. others were with much wide age ranges) and the evaluation methods (we examined the MS risk association with depression only among those who did not take anti-depressants, while other studies did not exclude them). has been proposed to describe a subset of depressive disorders that occurs in old age as a consequence of cerebrovascular disease [5, 22] . It has been estimated that approximately 3.4% or 2.64 million American adults 50-years and older might be considered having vascular depression [23] and treating late-life depression could improve cognitive function [24] . The change of white matter lesion volume is considered to have a causal association with vascular depression [25] , but it seems more research is needed to explore the bi-directional relationship between depression and vascular disease [26] . 
